Product Citation: Coordination of #Anle138b with silver yields a novel compound that selectively reduces C-terminally truncated αSyn in a Parkinson's disease model employing StressMarq’s #AlphaSynuclein PFFs.
Paper 🏝️ https://bit.ly/3KKfR62
Product 🌊 https://bit.ly/2u9YHV2
#neurodegeneration
In tests on mice, #anle138b delayed the progression of #Parkinson’s. A phase I clinical trial has been successfully completed. The researchers hope to achieve a disease modifying treatment with anle138b, that is to delay or even stop the progression of the disease.
The first steps have been taken, but there is still a long way to go before #anle138b can be used against #Parkinson’s and other #neurodegenerative diseases. #MODAG GmbH is responsible for further development and clinical testing. Since 2021, they collaborate with @tevapharm.
Learn more about #anle138b and the phase I trial here: www.modag.net/images/20201223_MODAG_Tr...
#Parkinson’s is one of the most common neurodegenerative diseases worldwide. In Germany alone, up to 400,000 people are affected. Researchers from @mpi_nat and @LMU_Muenchen developed a promising substance to treat Parkinson’s back in 2013: #anle138b. #worldparkinsonday
As they demonstrated, #Parkinson’s drug candidate #anle138b binds into a tube-shaped hole inside such a lipidic fibril. Their findings could open up new approaches to diagnosing and treating Parkinson’s disease. (2/2)
